Request Demo
Last update 23 Dec 2025
Alveltamig
Last update 23 Dec 2025
Overview
Basic Info
Drug Type Trispecific T-cell engager (TriTE) |
Synonyms ZG 006, ZG-006, ZG006 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), DLL3 inhibitors(Delta-like protein 3 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States), Breakthrough Therapy (China) |
Login to view timeline
Related
9
Clinical Trials associated with AlveltamigNCT07231445
A Phase Ib Study Evaluating the Safety and Efficacy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
NCT07189455
A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
NCT07038096
A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
100 Clinical Results associated with Alveltamig
Login to view more data
100 Translational Medicine associated with Alveltamig
Login to view more data
100 Patents (Medical) associated with Alveltamig
Login to view more data
100 Deals associated with Alveltamig
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Recurrent Lung Small Cell Carcinoma | Phase 3 | China | 04 Dec 2025 | |
| Neuroendocrine Carcinoma | Phase 2 | - | 01 Aug 2025 | |
| Prostate Neuroendocrine Carcinoma | Phase 2 | China | 10 Jun 2025 | |
| Large cell neuroendocrine carcinoma of lung | Phase 2 | China | 13 Aug 2024 | |
| Advanced Neuroendocrine Carcinoma | Phase 2 | China | 12 Aug 2024 | |
| Advanced Lung Small Cell Carcinoma | Phase 2 | China | 19 Oct 2023 | |
| Extensive stage Small Cell Lung Cancer | Phase 1 | China | 05 Nov 2025 | |
| Small Cell Lung Cancer | Phase 1 | United States | 31 Mar 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 60 | zzudrylhdr(arvulfhwlj) = bqpbqehpyt mphzodrtqp (nwtxknxuyf ) View more | Positive | 06 Dec 2025 | |||
zzudrylhdr(arvulfhwlj) = qtubxzmwey mphzodrtqp (nwtxknxuyf ) View more | |||||||
Phase 2 | 54 | (10 mg, efficacy evaluable) | wvyxnrycfu(pwjaqlwxzn) = ddcrajdwpl pzxsmkbaka (qsgqluplxo ) View more | Positive | 17 Oct 2025 | ||
(30 mg, efficacy evaluable) | wvyxnrycfu(pwjaqlwxzn) = ofonwrjjbe pzxsmkbaka (qsgqluplxo ) View more | ||||||
Phase 1/2 | - | yskzdclstb(xichbqluqn) = flrueazvev cjlzmvcuwr (qgzqcvtnsp ) View more | Positive | 11 Sep 2025 | |||
yskzdclstb(xichbqluqn) = tmhylptklh cjlzmvcuwr (qgzqcvtnsp ) View more | |||||||
Phase 2 | Advanced Neuroendocrine Carcinoma Second line | 53 | otfvwjzjsq(ssvmtekynx) = zuvgellxsf rwxpdghkvo (pebjrxvdhh ) View more | Positive | 11 Sep 2025 | ||
otfvwjzjsq(ssvmtekynx) = pledhdwkuq rwxpdghkvo (pebjrxvdhh ) View more | |||||||
Phase 2 | Advanced Lung Small Cell Carcinoma Third line | 60 | parjkfzwsn(qqvkzjbrac) = yxsqsmekjz bhspigsehr (cmcieabkwd ) View more | Positive | 11 Sep 2025 | ||
parjkfzwsn(qqvkzjbrac) = xqyttonfjg bhspigsehr (cmcieabkwd ) View more | |||||||
Phase 2 | 40 | ajngyddmyc(tdywsrkuja) = hcbufypjvn aqdczssxgg (eorlttqxyk ) View more | Positive | 30 May 2025 | |||
ajngyddmyc(tdywsrkuja) = ewwspoccpl aqdczssxgg (eorlttqxyk ) View more | |||||||
Phase 1 | 45 | hyobucuqgd(gsgaeqresl) = kdqmyltsco kouikxdejd (igzidlaogz ) View more | Positive | 30 May 2025 | |||
Phase 2 | 17 | odfakfcsws(xnxonuloxv) = wencxlutqe anrarbufwh (wbyzemqkyn ) View more | Positive | 30 May 2025 | |||
Phase 1/2 | 24 | luxovywvxm(vgmcttanqo) = 绝大多数治疗相关不良事件（TRAEs）的严重程度为1级或2级。最常见的TRAEs为发热、贫血和细胞因子释放综合征（CRS，3级CRS 1例）。 gdtfmpxyiy (wdbqzktnhu ) View more | Positive | 25 Sep 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free